CCR2 and familial pancreatic carcinoma: When compared to chemotherapy alone, a CCR2 antagonist, CCX827 (NCT02345408), coupled with a chemotherapeutic drugs, FOLFIRINOX, improved patients’ overall survival in advanced pancreatic cancer (211).